Stuart A. Arbuckle - 10 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
10 Feb 2023
Net transactions value
-$4,239,874
Form type
4
Filing time
14 Feb 2023, 15:53:14 UTC
Previous filing
03 Feb 2023
Next filing
16 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $992,481 -3,372 -3.5% $294.33 92,880 10 Feb 2023 Direct
transaction VRTX Common Stock Tax liability $1,786,577 -5,990 -6.4% $298.26 86,890 13 Feb 2023 Direct
transaction VRTX Common Stock Sale $72,628 -245 -0.28% $296.44 86,645 13 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $605,196 -2,028 -2.3% $298.42 84,617 13 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $532,384 -1,779 -2.1% $299.26 82,838 13 Feb 2023 Direct F1, F2, F5
transaction VRTX Common Stock Sale $250,609 -835 -1% $300.13 82,003 13 Feb 2023 Direct F1, F2, F6
holding VRTX Common Stock 140 10 Feb 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $296.44 (range $295.84 to $296.57).
F4 Open market sales reported on this line occurred at a weighted average price of $298.42 (range $297.85 to $298.80).
F5 Open market sales reported on this line occurred at a weighted average price of $299.26 (range $298.86 to $299.81).
F6 Open market sales reported on this line occurred at a weighted average price of $300.13 (range $299.93 to $300.53).